Table of Content

1. Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Protein Therapeutics Market

4. Market Overview
    4.1. Introduction
        4.1.1. Product Definition
        4.1.2. Industry Evolution / Developments
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Global Protein Therapeutics Market Analysis and Forecast, 2017–2031
        4.4.1. Market Revenue Projections (US$ Mn)
        4.4.2. Market Volume/Unit Shipments Projections
    4.5. Porter’s Five Force Analysis

5. Key Insights
    5.1. Therapeutic monoclonal antibodies approved or in review in the EU or US.
    5.2. Regulatory Scenario
    5.3. Key Products or Brand Analysis
    5.4. Technological Advances in Protein Therapeutics.
    5.5. Engineering protein-based therapeutics through structural and chemical design

6. Global Protein Therapeutics Market Analysis and Forecast, By Product
    6.1. Introduction & Definition
    6.2. Key Findings / Developments
    6.3. Market Value Forecast, by Product, 2017–2031
        6.3.1. Monoclonal Antibodies
        6.3.2. Enzyme Replacement Therapy
        6.3.3. Cytokines
            6.3.3.1. Interferons
            6.3.3.2. Interleukins
            6.3.3.3. Growth Factors
        6.3.4. Fusion Proteins
        6.3.5. Anti-coagulants
        6.3.6. Bone Morphogenetic Proteins (BMPs)
        6.3.7. Hormones
        6.3.8. Others (engineered protein scaffolds, etc.)
    6.4. Market Attractiveness Analysis, By Product

7. Global Protein Therapeutics Market Analysis and Forecast, By Application
    7.1. Introduction & Definition
    7.2. Key Findings / Developments
    7.3. Market Value Forecast, by Application, 2017–2031
        7.3.1. Metabolic Disorders
        7.3.2. Immunologic Disorders
        7.3.3. Hematological Disorders
        7.3.4. Cancer
        7.3.5. Genetic Disorders
    7.4. Market Attractiveness Analysis, By Application

8. Global Protein Therapeutics Market Analysis and Forecast, By Route of Administration
    8.1. Introduction & Definition
    8.2. Key Findings / Developments
    8.3. Market Value Forecast, by Route of Administration, 2017–2031
        8.3.1. Injectable Proteins
        8.3.2. Oral Proteins
    8.4. Market Attractiveness Analysis, By Route of Administration

9. Global Protein Therapeutics Market Analysis and Forecast, By Region
    9.1. Key Findings
    9.2. Market Value Forecast, by Region
        9.2.1. North America
        9.2.2. Europe
        9.2.3. Asia Pacific
        9.2.4. Latin America
        9.2.5. Middle East & Africa
    9.3. Market Attractiveness Analysis, By Region

10. North America Protein Therapeutics Market Analysis and Forecast
    10.1. Introduction
        10.1.1. Key Findings
    10.2. Market Value Forecast, by Product, 2017–2031
        10.2.1. Monoclonal Antibodies
        10.2.2. Enzyme Replacement Therapy
        10.2.3. Cytokines
            10.2.3.1. Interferons
            10.2.3.2. Interleukins
            10.2.3.3. Growth Factors
        10.2.4. Fusion Proteins
        10.2.5. Anti-coagulants
        10.2.6. Bone Morphogenetic Proteins (BMPs)
        10.2.7. Hormones
        10.2.8. Others (engineered protein scaffolds, etc.)
    10.3. Market Value Forecast, by Application, 2017–2031
        10.3.1. Metabolic Disorders
        10.3.2. Immunologic Disorders
        10.3.3. Hematological Disorders
        10.3.4. Cancer
        10.3.5. Genetic Disorders
    10.4. Market Value Forecast, by Route of Administration, 2017–2031
        10.4.1. Injectable Proteins
        10.4.2. Oral Proteins
    10.5. Market Value Forecast, by Country, 2017–2031
        10.5.1. U.S.
        10.5.2. Canada
    10.6. Market Attractiveness Analysis
        10.6.1. By Product
        10.6.2. By Application
        10.6.3. By Route of Administration
        10.6.4. By Country

11. Europe Protein Therapeutics Market Analysis and Forecast
    11.1. Introduction
        11.1.1. Key Findings
    11.2. Market Value Forecast, by Product, 2017–2031
        11.2.1. Monoclonal Antibodies
        11.2.2. Enzyme Replacement Therapy
        11.2.3. Cytokines
            11.2.3.1. Interferons
            11.2.3.2. Interleukins
            11.2.3.3. Growth Factors
        11.2.4. Fusion Proteins
        11.2.5. Anti-coagulants
        11.2.6. Bone Morphogenetic Proteins (BMPs)
        11.2.7. Hormones
        11.2.8. Others (engineered protein scaffolds, etc.)
    11.3. Market Value Forecast, by Application, 2017–2031
        11.3.1. Metabolic Disorders
        11.3.2. Immunologic Disorders
        11.3.3. Hematological Disorders
        11.3.4. Cancer
        11.3.5. Genetic Disorders
    11.4. Market Value Forecast, by Route of Administration, 2017–2031
        11.4.1. Injectable Proteins
        11.4.2. Oral Proteins
    11.5. Market Value Forecast, by Country/Sub-region, 2017–2031
        11.5.1. Germany
        11.5.2. U.K.
        11.5.3. France
        11.5.4. Italy
        11.5.5. Spain
        11.5.6. Rest of Europe
    11.6. Market Attractiveness Analysis
        11.6.1. By Product
        11.6.2. By Application
        11.6.3. By Route of Administration
        11.6.4. By Country/Sub-region
12. Asia Pacific Protein Therapeutics Market Analysis and Forecast
    12.1. Introduction
        12.1.1. Key Findings
    12.2. Market Value Forecast, by Product, 2017–2031
        12.2.1. Monoclonal Antibodies
        12.2.2. Enzyme Replacement Therapy
        12.2.3. Cytokines
            12.2.3.1. Interferons
            12.2.3.2. Interleukins
            12.2.3.3. Growth Factors
        12.2.4. Fusion Proteins
        12.2.5. Anti-coagulants
        12.2.6. Bone Morphogenetic Proteins (BMPs)
        12.2.7. Hormones
        12.2.8. Others (engineered protein scaffolds, etc.)
    12.3. Market Value Forecast, by Application, 2017–2031
        12.3.1. Metabolic Disorders
        12.3.2. Immunologic Disorders
        12.3.3. Hematological Disorders
        12.3.4. Cancer
        12.3.5. Genetic Disorders
    12.4. Market Value Forecast, by Route of Administration, 2017–2031
        12.4.1. Injectable Proteins
        12.4.2. Oral Proteins
    12.5. Market Value Forecast, by Country/Sub-region, 2017–2031
        12.5.1. China
        12.5.2. India
        12.5.3. Japan
        12.5.4. Australia & New Zealand
        12.5.5. Rest of Asia Pacific
    12.6. Market Attractiveness Analysis
        12.6.1. By Product
        12.6.2. By Application
        12.6.3. By Route of Administration
        12.6.4. By Country/Sub-region
13. Latin America Protein Therapeutics Market Analysis and Forecast
    13.1. Introduction
        13.1.1. Key Findings
    13.2. Market Value Forecast, by Product, 2017–2031
        13.2.1. Monoclonal Antibodies
        13.2.2. Enzyme Replacement Therapy
        13.2.3. Cytokines
            13.2.3.1. Interferons
            13.2.3.2. Interleukins
            13.2.3.3. Growth Factors
        13.2.4. Fusion Proteins
        13.2.5. Anti-coagulants
        13.2.6. Bone Morphogenetic Proteins (BMPs)
        13.2.7. Hormones
        13.2.8. Others (engineered protein scaffolds, etc.)
    13.3. Market Value Forecast, by Application, 2017–2031
        13.3.1. Metabolic Disorders
        13.3.2. Immunologic Disorders
        13.3.3. Hematological Disorders
        13.3.4. Cancer
        13.3.5. Genetic Disorders
    13.4. Market Value Forecast, by Route of Administration, 2017–2031
        13.4.1. Injectable Proteins
        13.4.2. Oral Proteins
    13.5. Market Value Forecast, by Country/Sub-region, 2017–2031
        13.5.1. Brazil
        13.5.2. Mexico
        13.5.3. Rest of Latin America
    13.6. Market Attractiveness Analysis
        13.6.1. By Product
        13.6.2. By Application
        13.6.3. By Route of Administration
        13.6.4. By Country/Sub-region
14. Middle East & Africa Protein Therapeutics Market Analysis and Forecast
    14.1. Introduction
        14.1.1. Key Findings
    14.2. Market Value Forecast, by Product, 2017–2031
        14.2.1. Monoclonal Antibodies
        14.2.2. Enzyme Replacement Therapy
        14.2.3. Cytokines
            14.2.3.1. Interferons
            14.2.3.2. Interleukins
            14.2.3.3. Growth Factors
        14.2.4. Fusion Proteins
        14.2.5. Anti-coagulants
        14.2.6. Bone Morphogenetic Proteins (BMPs)
        14.2.7. Hormones
        14.2.8. Others (engineered protein scaffolds, etc.)
    14.3. Market Value Forecast, by Application, 2017–2031
        14.3.1. Metabolic Disorders
        14.3.2. Immunologic Disorders
        14.3.3. Hematological Disorders
        14.3.4. Cancer
        14.3.5. Genetic Disorders
    14.4. Market Value Forecast, by Route of Administration, 2017–2031
        14.4.1. Injectable Proteins
        14.4.2. Oral Proteins
    14.5. Market Value Forecast, by Country/Sub-region, 2017–2031
        14.5.1. GCC Countries
        14.5.2. South Africa
        14.5.3. Rest of Middle East & Africa
    14.6. Market Attractiveness Analysis
        14.6.1. By Product
        14.6.2. By Application
        14.6.3. By Route of Administration
        14.6.4. By Country/Sub-region

15. Competition Landscape
    15.1. Market Player – Competition Matrix (By Tier and Size of companies)
    15.2. Market Share Analysis By Company (2022)
    15.3. Company Profiles
        15.3.1. Thermo Fisher Scientific, Inc.
            15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.1.2. Material Portfolio
            15.3.1.3. Financial Overview
            15.3.1.4. SWOT Analysis
            15.3.1.5. Strategic Overview
        15.3.2. Genzyme Corporation (Sanofi)
            15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.2.2. Material Portfolio
            15.3.2.3. Financial Overview
            15.3.2.4. SWOT Analysis
            15.3.2.5. Strategic Overview
        15.3.3. AbbVie, Inc.
            15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.3.2. Material Portfolio
            15.3.3.3. Financial Overview
            15.3.3.4. SWOT Analysis
            15.3.3.5. Strategic Overview
        15.3.4. Sanofi
            15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.4.2. Material Portfolio
            15.3.4.3. Financial Overview
            15.3.4.4. SWOT Analysis
            15.3.4.5. Strategic Overview
        15.3.5. Leadiant Biosciences
            15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.5.2. Material Portfolio
            15.3.5.3. Financial Overview
            15.3.5.4. SWOT Analysis
            15.3.5.5. Strategic Overview
        15.3.6. Takeda Pharmaceutical Company Limited
            15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.6.2. Material Portfolio
            15.3.6.3. Financial Overview
            15.3.6.4. SWOT Analysis
            15.3.6.5. Strategic Overview
        15.3.7. Amicus Therapeutics
            15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.7.2. Material Portfolio
            15.3.7.3. Financial Overview
            15.3.7.4. SWOT Analysis
            15.3.7.5. Strategic Overview
        15.3.8. Bayer AG
            15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.8.2. Material Portfolio
            15.3.8.3. Financial Overview
            15.3.8.4. SWOT Analysis
            15.3.8.5. Strategic Overview
        15.3.9. Bristol-Myers Squibb
            15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.9.2. Material Portfolio
            15.3.9.3. Financial Overview
            15.3.9.4. SWOT Analysis
            15.3.9.5. Strategic Overview
        15.3.10. DAIICHI SANKYO COMPANY
            15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.10.2. Material Portfolio
            15.3.10.3. Financial Overview
            15.3.10.4. SWOT Analysis
            15.3.10.5. Strategic Overview
        15.3.11. Abbott
            15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.11.2. Material Portfolio
            15.3.11.3. Financial Overview
            15.3.11.4. SWOT Analysis
            15.3.11.5. Strategic Overview
        15.3.12. Sanofi
            15.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.12.2. Material Portfolio
            15.3.12.3. Financial Overview
            15.3.12.4. SWOT Analysis
            15.3.12.5. Strategic Overview



List of Figures

List of Figures

Figure 01: Global Protein Therapeutics Market Size (US$ Mn) Forecast, 2017-2031

Figure 02: Global Protein Therapeutics Market Value Share, by Product (2022)

Figure 03: Global Protein Therapeutics Market Value Share, by Application (2022)

Figure 04: Global Protein Therapeutics Market Value Share, by End-user (2022)

Figure 05: Global Protein Therapeutics Market Value Share, by Region (2022)

Figure 06: Global Protein Therapeutics Market Value Share, by Application, 2022 and 2031

Figure 07: Global Protein Therapeutics Market Attractiveness Analysis, by Application, 2017-2031

Figure 08: Global Protein Therapeutics Market Value Share, by Product, 2022 and 2031

Figure 09: Global Protein Therapeutics Market Attractiveness Analysis, by Product, 2017-2031

Figure 10: Global Protein Therapeutics Market Value Share, by Route of Administration, 2022 and 2031

Figure 11: Global Protein Therapeutics Market Attractiveness Analysis, by Route of Administration, 2017-2031

Figure 12: Global Protein Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017-2031

Figure 13: Global Protein Therapeutics Market Value Share, by Region, 2017-2031

Figure 14: Global Protein Therapeutics Market Attractiveness Analysis, by Region, 2017-2031

Figure 15: North America Protein Therapeutics Market Value Share, by Application, 2022 and 2031

Figure 16: North America Protein Therapeutics Market Attractiveness Analysis, by Application, 2017-2031

Figure 17: North America Protein Therapeutics Market Value Share, by Product, 2022 and 2031

Figure 18: North America Protein Therapeutics Market Attractiveness Analysis, by Product, 2017-2031

Figure 19: North America Protein Therapeutics Market Value Share, by Route of Administration, 2022 and 2031

Figure 20: North America Protein Therapeutics Market Attractiveness Analysis, by Route of Administration, 2017-2031

Figure 21: North America Protein Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017-2031

Figure 22: North America Protein Therapeutics Market Value Share, by Country, 2017-2031

Figure 23: North America Protein Therapeutics Market Attractiveness Analysis, by Country, 2017-2031

Figure 24: Europe Protein Therapeutics Market Value Share, by Application, 2022 and 2031

Figure 25: Europe Protein Therapeutics Market Attractiveness Analysis, by Application, 2017-2031

Figure 26 : Europe Protein Therapeutics Market Value Share, by Product, 2022 and 2031

Figure 27: Europe Protein Therapeutics Market Attractiveness Analysis, by Product, 2017-2031

Figure 28: Europe Protein Therapeutics Market Value Share, by Route of Administration, 2022 and 2031

Figure 29: Europe Protein Therapeutics Market Attractiveness Analysis, by Route of Administration, 2017-2031

Figure 30: Europe Protein Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017-2031

Figure 31: Europe Protein Therapeutics Market Value Share, by Country/Sub-region, 2017-2031

Figure 32: Europe Protein Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2017-2031

Figure 33: Asia Pacific Protein Therapeutics Market Value Share, by Application, 2022 and 2031

Figure 34: Asia Pacific Protein Therapeutics Market Attractiveness Analysis, by Application, 2017-2031

Figure 35: Asia Pacific Protein Therapeutics Market Value Share, by Product, 2022 and 2031

Figure 36: Asia Pacific Protein Therapeutics Market Attractiveness Analysis, by Product, 2017-2031

Figure 37: Asia Pacific Protein Therapeutics Market Value Share, by Route of Administration, 2022 and 2031

Figure 38: Asia Pacific Protein Therapeutics Market Attractiveness Analysis, by Route of Administration, 2017-2031

Figure 39: Asia Pacific Protein Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017-2031

Figure 40 : Asia Pacific Protein Therapeutics Market Value Share, by Country/Sub-region, 2017-2031

Figure 41: Asia Pacific Protein Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2017-2031

Figure 42: Latin America Protein Therapeutics Market Value Share, by Application, 2022 and 2031

Figure 43: Latin America Protein Therapeutics Market Attractiveness Analysis, by Application, 2017-2031

Figure 44: Latin America Protein Therapeutics Market Value Share, by Product, 2022 and 2031

Figure 45: Latin America Protein Therapeutics Market Attractiveness Analysis, by Product, 2017-2031

Figure 46: Latin America Protein Therapeutics Market Value Share, by Route of Administration, 2022 and 2031

Figure 47: Latin America Protein Therapeutics Market Attractiveness Analysis, by Route of Administration, 2017-2031

Figure 48: Latin America Protein Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017-2031

Figure 45: Latin America Protein Therapeutics Market Value Share, by Country/Sub-region, 2017-2031

Figure 50: Latin America Protein Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2017-2031

Figure 51: Middle East & Africa Protein Therapeutics Market Value Share, by Application, 2022 and 2031

Figure 52: Middle East & Africa Protein Therapeutics Market Attractiveness Analysis, by Application, 2017-2031

Figure 53: Middle East & Africa Protein Therapeutics Market Value Share, by Product, 2022 and 2031

Figure 54: Middle East & Africa Protein Therapeutics Market Attractiveness Analysis, by Product, 2017-2031

Figure 55: Middle East & Africa Protein Therapeutics Market Value Share, by Route of Administration, 2022 and 2031

Figure 56: Middle East & Africa Protein Therapeutics Market Attractiveness Analysis, by Route of Administration, 2017-2031

Figure 57: Middle East & Africa Protein Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017-2031

Figure 58: Middle East & Africa Protein Therapeutics Market Value Share, by Country/Sub-region, 2017-2031

Figure 59: Middle East & Africa Protein Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2017-2031

List of Tables

List of Tables

Table 01: Global Protein Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017-2031

Table 02: Global Protein Therapeutics Market Value (US$ Mn) Forecast, by Product, 2017-2031

Table 03: Global Protein Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031

Table 04: Global Protein Therapeutics Market Value (US$ Mn) Forecast, by Region, 2017-2031

Table 05: North America Protein Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017-2031

Table 06: North America Protein Therapeutics Market Value (US$ Mn) Forecast, by Product, 2017-2031

Table 07: North America Protein Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031

Table 08: North America Protein Therapeutics Market Value (US$ Mn) Forecast, by Country, 2017-2031

Table 09: Europe Protein Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017-2031

Table 10: Europe Protein Therapeutics Market Value (US$ Mn) Forecast, by Product, 2017-2031

Table 11: Europe Protein Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031

Table 12: Europe Protein Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

Table 13: Asia Pacific Protein Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017-2031

Table 14: Asia Pacific Protein Therapeutics Market Value (US$ Mn) Forecast, by Product, 2017-2031

Table 15: Asia Pacific Protein Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031

Table 16: Asia Pacific Protein Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

Table 17: Latin America Protein Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017-2031

Table 18: Latin America Protein Therapeutics Market Value (US$ Mn) Forecast, by Product, 2017-2031

Table 19: Latin America Protein Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031

Table 20: Latin America Protein Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

Table 21: Middle East & Africa Protein Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017-2031

Table 22: Middle East & Africa Protein Therapeutics Market Value (US$ Mn) Forecast, by Product, 2017-2031

Table 23: Middle East & Africa Protein Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2017-2031

Table 24: Middle East & Africa Protein Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031